Skip to main content
Infant Formula Recall Retirada del mercado de fórmula infantil

ALERT: ByHeart Recalls Whole Nutrition Infant Formula. Read more

AVISO IMPORTANTE: ByHeart retira del mercado su fórmula infantil Whole Nutrition. Aprender más

Transportation Update Actualización de transporte

Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.

Learn more here

For other questions, please call Member Services at the number on the back of your member ID card.

A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).

Obtenga más información AQUI

Si tiene otras preguntas, llame a Servicios para Miembros al número que aparece en la parte posterior de su tarjeta de identificación del miembro.

Change in Preferred Drug List Status for Stimulants and Related Agents Drug Class

Date: August 12, 2025

Attention: All Providers

Effective dates: August 11 and 18, 2025

Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective August 11 and 18, 2025, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from generic methylphenidate patch products and certain methylphenidate products on the preferred drug list (PDL).

This change is in response to:

  • A reported shortage of the active ingredient in Daytrana patch products, as reported by the manufacturer, Noven, and,
  • Ongoing drug shortages of various brand and generic methylphenidate products.
Impacted MedicationType of ChangeEffective Date
METHYLPHENIDATE 10 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 15 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 20 MG/9HR PTCHGeneric now preferredAugust 11, 2025
METHYLPHENIDATE 30 MG/9HR PTCHGeneric now preferredAugust 11, 2025
COTEMPLA XR-ODT 8.6 MG TABLETBrand now preferredAugust 18, 2025
COTEMPLA XR-ODT 17.3 MG TABLETBrand now preferredAugust 18, 2025
COTEMPLA XR-ODT 25.9 MG TABLETBrand now preferredAugust 18, 2025
QUILLICHEW ER 20 MG CHEW TABBrand now preferredAugust 18, 2025
QUILLICHEW ER 30 MG CHEW TABBrand now preferredAugust 18, 2025
QUILLICHEW ER 40 MG CHEW TABGeneric now preferredAugust 18, 2025
METHYLPHENIDATE ER 10 MG TABGeneric now preferredAugust 18, 2025
METHYLPHENIDATE ER 20 MG TABGeneric now preferredAugust 18, 2025

How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.

Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org

For access to all provider alerts,log into: www.texaschildrenshealthplan.org/provideralerts.